Medicare Enrolled
Dr. Julie Kurek
Neurology · Augusta, GA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kurek from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kurek?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kurek
Dr. Julie Kurek is a neurology specialist in Augusta, GA, with 16 years of NPI registration. Based on federal Medicare data, Dr. Kurek performed 744 Medicare services across 418 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kurek received a total of $23,639 from 60 pharmaceutical and/or device companies across 541 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kurek is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 35% volume in GA
$23,639 industry payments
Medicare Practice Summary
Medicare Utilization ↗744
Medicare services
Top 35% in GA for neurology
418
Unique beneficiaries
$71
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~46 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
268 | $103 | $246 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 87 | $14 | $76 |
| Chemical nerve block for neck muscles Injection of a chemical agent to paralyze specific muscles on the side of the neck, excluding the voice box. |
64 | $105 | $229 |
| Brain stimulator programming, additional 15 minutes Electronic analysis and programming of an implanted brain neurostimulator generator by a qualified health professional. This code applies to each additional 15-minute increment beyond the initial service. |
62 | $33 | $110 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
60 | $23 | $71 |
| Brain stimulator programming, first 15 minutes Electronic analysis of an implanted brain, spinal cord, or peripheral neurostimulator generator. This service includes programming the brain stimulator by a qualified health professional for the first 15 minutes. |
57 | $36 | $126 |
| Chemical nerve block for facial paralysis Injection of a chemical agent to paralyze specific nerves or muscles on the side of the face. |
33 | $118 | $529 |
| Electronic analysis of implanted neurostimulator Electronic evaluation of an implanted brain, spinal cord, or peripheral nerve stimulator device. |
32 | $14 | $149 |
| Chemical paralysis of salivary glands, bilateral Injection of a chemical agent to paralyze the salivary glands on both sides of the mouth. |
28 | $79 | $261 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
27 | $62 | $172 |
| New patient office visit, complex (60-74 min) | 26 | $128 | $368 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$23,639
Total received (2018-2024)
Avg $3,377/year across 7 years
Top 14% in GA for neurology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
541
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,765 (58.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$8,129 (34.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,745 (7.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,660
2023
$1,841
2022
$3,401
2021
$1,632
2020
$1,196
2019
$10,144
2018
$3,767
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$514
Teva Pharmaceuticals USA, Inc.
$176
Boston Scientific Corporation
$166
Alexion Pharmaceuticals, Inc.
$106
ARGENX US, INC.
$90
Neurocrine Biosciences, Inc.
$81
AstraZeneca Pharmaceuticals LP
$69
Ipsen Biopharmaceuticals, Inc
$52
PFIZER INC.
$48
ACADIA Pharmaceuticals Inc
$40
Lundbeck LLC
$32
Amneal Pharmaceuticals LLC
$30
SK Life Science, Inc.
$28
Kyowa Kirin, Inc.
$27
Merz Pharmaceuticals, LLC
$27
Averitas Pharma Inc.
$27
Takeda Pharmaceuticals U.S.A., Inc.
$25
REVANCE THERAPEUTICS, INC.
$24
Otsuka America Pharmaceutical, Inc.
$23
Amicus Therapeutics, Inc.
$22
Kedrion Biopharma, Inc.
$21
Lilly USA, LLC
$16
Octapharma USA, Inc.
$14
Top 3 companies account for 51.5% of 2024 payments
All-time payments by company (2018-2024) ›
US WorldMeds, LLC
$7,554
Medtronic USA, Inc.
$2,559
Neurocrine Biosciences, Inc.
$2,227
Boston Scientific Corporation
$1,580
ABBVIE INC.
$1,280
Teva Pharmaceuticals USA, Inc.
$1,077
Abbott Laboratories
$924
MDD US Operations, LLC
$702
Allergan Inc.
$417
ACADIA Pharmaceuticals Inc
$400
Sunovion Pharmaceuticals Inc.
$362
Lundbeck LLC
$286
Adamas Pharmaceuticals, Inc.
$271
Alexion Pharmaceuticals, Inc.
$262
ARGENX US, INC.
$252
Amneal Pharmaceuticals LLC
$241
Ipsen Biopharmaceuticals, Inc
$232
MITSUBISHI TANABE PHARMA AMERICA, INC.
$225
Allergan, Inc.
$206
Merz Pharmaceuticals, LLC
$197
Amgen Inc.
$188
Avanir Pharmaceuticals, Inc.
$187
Eisai Inc.
$185
AbbVie Inc.
$159
EISAI INC.
$138
Avion Pharmaceuticals
$137
PFIZER INC.
$97
Otsuka America Pharmaceutical, Inc.
$92
Medtronic, Inc.
$87
Kyowa Kirin, Inc.
$83
UCB, Inc.
$82
Saol Therapeutics Inc.
$79
AstraZeneca Pharmaceuticals LP
$69
Takeda Pharmaceuticals U.S.A., Inc.
$67
JAZZ PHARMACEUTICALS INC.
$63
SK Life Science, Inc.
$59
AbbVie, Inc.
$56
Amylyx Pharmaceuticals, Inc.
$54
Biohaven Pharmaceutical Holding Company Ltd.
$50
Biogen, Inc.
$50
Acorda Therapeutics, Inc
$38
Impax Laboratories, Inc.
$36
Neurelis, Inc.
$31
Averitas Pharma Inc.
$27
REVANCE THERAPEUTICS, INC.
$24
Amicus Therapeutics, Inc.
$22
HOSPIRA, INC.
$22
Kedrion Biopharma, Inc.
$21
Scilex Pharmaceuticals Inc.
$21
GE Healthcare
$19
Baxter Healthcare
$17
E.R. Squibb & Sons, L.L.C.
$17
Lilly USA, LLC
$16
ARBOR PHARMACEUTICALS, INC.
$14
CSL Behring
$14
Octapharma USA, Inc.
$14
Janssen Pharmaceuticals, Inc
$14
Merz North America, Inc.
$13
GENZYME CORPORATION
$12
NATUS MEDICAL INCORPORATED
$11
Top 3 companies account for 52.2% of all-time payments
Associated products mentioned in payments ›
ACTIVA · AJOVY · AMYVID · APOKYN · APTIOM · AUSTEDO · Aimovig · Albuked · Austedo XR · BOTOX · BOTOX THERAPEUTIC · DAXXIFY · DUOPA · DYSPORT · Deep Brain Stimulation · Dhivy · Duopa · Dysport · ELIQUIS · EPIDIOLEX · Fycompa · GAMMAGARD · GENERAL DBS · GENERAL - DBS · GENERAL DBS · GOCOVRI · HYQVIA · Hizentra · Horizant · INBRIJA · INGREZZA · IPX203 · Infinity DBS Pulse Generators · KYNMOBI · LATUDA · Leqembi · Lioresal (baclofen) · MYOBLOC · NORTHERA · NOURIANZ · NUEDEXTA · NUPLAZID · NURTEC ODT · Neuromodulation Dspsbls and Accs · Nourianz · Nuedexta · Ongentys · PANZYGA · POMPE - DISEASE · Pombiliti · QULIPTA · QUTENZA · RADICAVA · RELYVRIO · REXULTI · RYTARY · SOLIRIS · SPINRAZA · SenSight · Skyclarys · UBRELVY · ULTOMIRIS · VALTOCO · VYALEV · VYEPTI · VYVGART · VYVGART HYTRULO · Vimpat · WAINUA · XARELTO · XEOMIN · Xadago · Xeomin
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (58%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Neurologists within 10 mi
83
Per 100K population
40.3
County median income
$53,197
Nearest hospital
WELLSTAR MCG HEALTH, AFFILIATED WITH MED COL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kurek is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 14% of GA peers, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kurek experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Kurek performed 268 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kurek receive payments from pharmaceutical companies?
Yes. Dr. Kurek received a total of $23,639 from 60 companies across 541 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kurek's costs compare to other neurologists in Augusta?
Dr. Kurek's average Medicare payment per service is $71. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kurek) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Neurology
Common procedures, typical costs, and what industry payments mean in neurology.
Same specialty & city
Neurologists in Augusta
Browse neurologists in Augusta ranked by procedure volume and transparency data.
Highest volume
Top Neurologists in GA
Neurologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Neurologists in GA
Which GA neurologists receive the most from drug and device companies.
By company
US WorldMeds, LLC Payments to Doctors
See all physicians who received payments from US WorldMeds, LLC.
By company
Medtronic USA, Inc. Payments to Doctors
See all physicians who received payments from Medtronic USA, Inc.
By company
Neurocrine Biosciences, Inc. Payments to Doctors
See all physicians who received payments from Neurocrine Biosciences, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology